MicroRNA‑654‑3p enhances cisplatin sensitivity by targeting QPRT and inhibiting the PI3K/AKT signaling pathway in ovarian cancer cells

Niu,Yi‑Chao; Tong,Jing; Shi,Xiao‑Fei; Zhang,Ting

doi:10.3892/etm.2020.8878

MicroRNA‑654‑3p enhances cisplatin sensitivity by targeting QPRT and inhibiting the PI3K/AKT signaling pathway in ovarian cancer cells

Authors:
- Yi‑Chao Niu
- Jing Tong
- Xiao‑Fei Shi
- Ting Zhang
View Affiliations

Affiliations: Center for Reproductive Medicine, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200135, P.R. China, Department of Gynecology, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai 200126, P.R. China
Published online on: June 11, 2020 https://doi.org/10.3892/etm.2020.8878
Pages: 1467-1479
Copyright: © Niu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Dysregulation of microRNAs serves a crucial role in the chemosensitivity to cisplatin (DDP) in ovarian cancer (OVC). The abnormal expression of microRNA (miR)‑654‑3p has been reported in several types of human cancer. However, the association between miR‑654‑3p and cisplatin resistance in human OVC remains unclear. The present study aimed to investigate the role and mechanism of miR‑654‑3p in DDP resistance in OVC. The results demonstrated that miR‑654‑3p was significantly downregulated in ovarian cancer tissues and cells, as well as DDP‑resistant IGROV‑1/DDP cells, compared with adjacent non‑tumoral tissue and IOSE386 cells. Overexpression of miR‑654‑3p significantly suppressed the proliferation and migration of ovarian cancer cells and increased the sensitivity of IGROV‑1/DDP cells to DDP. Luciferase reporter assay demonstrated that quinolinate phosphoribosyl transferase (QPRT) was a target of miR‑654‑3p; overexpression of miR‑654‑3p inhibited QPRT expression by binding to the 3'‑untranslated region of QPRT. In addition, inhibition of miR‑654‑3p reversed the suppressive effects of QPRT‑targeting short interfering RNA on the proliferation and chemoresistance of ovarian cancer cells. Therefore, the results of the present study revealed a previously unrecognized regulatory mechanism that miR‑654‑3p enhances DDP sensitivity of OVC cells by downregulating QPRT expression; in addition, the present study highlighted the therapeutic implications of miR‑654‑3p upregulation in OVC.

View Figures

View References

1	Cao L, Wan Q, Li F and Tang CE: miR-363 inhibits cisplatin chemoresistance of epithelial ovarian cancer by regulating snail-induced epithelial-mesenchymal transition. BMB Rep. 51:456–461. 2018.PubMed/NCBI View Article : Google Scholar
2	GBD 2015 LRI Collaborators;. Troeger C, Forouzanfar M, Rao PC, Khalil I, Brown A, Swartz S, Fullman N, Mosser J, Thompson RL, et al: Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: A systematic analysis for the Global Burden of Disease Study 2015. Lancet Infect Dis. 17:1133–1161. 2017.PubMed/NCBI View Article : Google Scholar
3	Liu R, Guo H and Lu S: miR-335-5p restores cisplatin sensitivity in ovarian cancer cells through targeting BCL2L2. Cancer Med. 7:4598–4609. 2018.PubMed/NCBI View Article : Google Scholar
4	Feng X, Liu N, Deng S, Zhang D, Wang K and Lu M: miR-199a modulates cisplatin resistance in ovarian cancer by targeting Hif1alpha. Onco Targets Ther. 10:5899–5906. 2017.PubMed/NCBI View Article : Google Scholar
5	Liu Y, Han S, Li Y, Liu Y, Zhang D, Li Y and Zhang J: MicroRNA-20a contributes to cisplatin-resistance and migration of OVCAR3 ovarian cancer cell line. Oncol Lett. 14:1780–1786. 2017.PubMed/NCBI View Article : Google Scholar
6	Teng Y, Zuo X, Hou M, Zhang Y, Li C, Luo W and Li X: A double-negative feedback interaction between microRNA-29b and DNMT3A/3B contributes to ovarian cancer progression. Cell Physiol Biochem. 39:2341–2352. 2016.PubMed/NCBI View Article : Google Scholar
7	Zou J, Yin F, Wang Q, Zhang W and Li L: Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cancer. Int J Clin Exp Pathol. 8:6847–6858. 2015.PubMed/NCBI
8	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004.PubMed/NCBI View Article : Google Scholar
9	Inoue K, Deng Z, Chen Y, Giannopoulou E, Xu R, Gong S, Greenblatt MB, Mangala LS, Lopez-Berestein G, Kirsch DG, et al: Bone protection by inhibition of microRNA-182. Nat Commun. 9(4108)2018.PubMed/NCBI View Article : Google Scholar
10	Hayes J, Peruzzi PP and Lawler S: MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol Med. 20:460–469. 2014.PubMed/NCBI View Article : Google Scholar
11	Olive V, Minella AC and He L: Outside the coding genome, mammalian microRNAs confer structural and functional complexity. Sci Signal. 8(re2)2015.PubMed/NCBI View Article : Google Scholar
12	Ju J: Implications of miRNAs in colorectal cancer chemoresistance. Int Drug Discov. 2011(pii: 2063)2011.PubMed/NCBI
13	Kutanzi KR, Yurchenko OV, Beland FA, Checkhun VF and Pogribny IP: MicroRNA-mediated drug resistance in breast cancer. Clin Epigenetics. 2:171–185. 2011.PubMed/NCBI View Article : Google Scholar
14	Siddik ZH: Cisplatin Mode of cytotoxic action and molecular basis of resistance. Oncogene. 22:7265–7279. 2003.PubMed/NCBI View Article : Google Scholar
15	Deng H, Qianqian G, Ting J and Aimin Y: miR-539 enhances chemosensitivity to cisplatin in non-small cell lung cancer by targeting DCLK1. Biomed Pharmacother. 106:1072–1081. 2018.PubMed/NCBI View Article : Google Scholar
16	Zhao Y, Ma K, Yang S, Zhang X, Wang F, Zhang X, Liu H and Fan Q: MicroRNA-125a-5p enhances the sensitivity of esophageal squamous cell carcinoma cells to cisplatin by suppressing the activation of the STAT3 signaling pathway. Int J Oncol. 53:644–658. 2018.PubMed/NCBI View Article : Google Scholar
17	Shi X, Xiao L, Mao X, He J, Ding Y, Huang J, Peng C and Xu Z: miR-205-5p mediated downregulation of PTEN contributes to cisplatin resistance in C13K human ovarian cancer cells. Front Genet. 9(555)2018.PubMed/NCBI View Article : Google Scholar
18	Deb B, Uddin A and Chakraborty S: miRNAs and ovarian cancer: An overview. J Cell Physiol. 233:3846–3854. 2018.PubMed/NCBI View Article : Google Scholar
19	Tan YY, Xu XY, Wang JF, Zhang CW and Zhang SC: miR-654-5p attenuates breast cancer progression by targeting EPSTI1. Am J Cancer Res. 6:522–532. 2016.PubMed/NCBI
20	Geraldo MV, Nakaya HI and Kimura ET: Down-regulation of 14q32-encoded miRNAs and tumor suppressor role for miR-654-3p in papillary thyroid cancer. Oncotarget. 8:9597–9607. 2017.PubMed/NCBI View Article : Google Scholar
21	Xu C, Zheng Y, Lian D, Ye S, Yang J and Zeng Z: Analysis of microRNA expression profile identifies novel biomarkers for non-small cell lung cancer. Tumori. 101:104–110. 2015.PubMed/NCBI View Article : Google Scholar
22	Lu M, Wang C, Chen W, Mao C and Wang J: miR-654-5p targets GRAP to promote proliferation, metastasis, and chemoresistance of oral squamous cell carcinoma through Ras/MAPK signaling. DNA Cell Biol. 37:381–388. 2018.PubMed/NCBI View Article : Google Scholar
23	Zhang S, Zhang X, Fu X, Li W, Xing S and Yang Y: Identification of common differentially-expressed miRNAs in ovarian cancer cells and their exosomes compared with normal ovarian surface epithelial cell cells. Oncol Lett. 16:2391–2401. 2018.PubMed/NCBI View Article : Google Scholar
24	Arrighetti N, Cossa G, De Cecco L, Stucchi S, Carenini N, Corna E, Gandellini P, Zaffaroni N, Perego P and Gatti L: PKC-alpha modulation by miR-483-3p in platinum-resistant ovarian carcinoma cells. Toxicol Appl Pharmacol. 310:9–19. 2016.PubMed/NCBI View Article : Google Scholar
25	Smyth GK: Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 3(Article3)2004.PubMed/NCBI View Article : Google Scholar
26	Yao J, Zhang X, Li J, Zhao D, Gao B, Zhou H, Gao S and Zhang L: Silencing TRIP13 inhibits cell growth and metastasis of hepatocellular carcinoma by activating of TGF-β1/smad3. Cancer Cell Int. 18(208)2018.PubMed/NCBI View Article : Google Scholar
27	Vert JP, Foveau N, Lajaunie C and Vandenbrouck Y: An accurate and interpretable model for siRNA efficacy prediction. BMC Bioinformatics. 7(520)2006.PubMed/NCBI View Article : Google Scholar
28	Wang Z and Zhu F: MicroRNA-100 is involved in shrimp immune response to white spot syndrome virus (WSSV) and Vibrio alginolyticus infection. Sci Rep. 7(42334)2017.PubMed/NCBI View Article : Google Scholar
29	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
30	Amini-Farsani Z, Sangtarash MH, Shamsara M and Teimori H: miR-221/222 promote chemoresistance to cisplatin in ovarian cancer cells by targeting PTEN/PI3K/AKT signaling pathway. Cytotechnology. 70:203–213. 2018.PubMed/NCBI View Article : Google Scholar
31	Bugide S, Gonugunta VK, Penugurti V, Malisetty VL, Vadlamudi RK and Manavathi B: HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation. Cell Oncol (Dordr). 40:133–144. 2017.PubMed/NCBI View Article : Google Scholar
32	Ullmark T, Montano G, Jarvstrat L, Jernmark Nilsson H, Håkansson E, Drott K, Nilsson B, Vidovic K and Gullberg U: Anti-apoptotic quinolinate phosphoribosyltransferase (QPRT) is a target gene of Wilms' tumor gene 1 (WT1) protein in leukemic cells. Biochem Biophys Res Commun. 482:802–807. 2017.PubMed/NCBI View Article : Google Scholar
33	Yu X, Zheng H, Chan MT and Wu WK: Modulation of chemoresponsiveness to platinum-based agents by microRNAs in cancer. Am J Cancer Res. 7:1769–1778. 2017.PubMed/NCBI
34	Samuel P, Pink RC, Brooks SA and Carter DR: miRNAs and ovarian cancer: A miRiad of mechanisms to induce cisplatin drug resistance. Expert Rev Anticancer Ther. 16:57–70. 2016.PubMed/NCBI View Article : Google Scholar
35	Cai J, Yang C, Yang Q, Ding H, Jia J, Guo J, Wang J and Wang Z: Deregulation of let-7e in epithelial ovarian cancer promotes the development of resistance to cisplatin. Oncogenesis. 2(e75)2013.PubMed/NCBI View Article : Google Scholar
36	Zhang Y, Huang S, Guo Y and Li L: miR-1294 confers cisplatin resistance in ovarian Cancer cells by targeting IGF1R. Biomed Pharmacother. 106:1357–1363. 2018.PubMed/NCBI View Article : Google Scholar
37	Vera O, Jimenez J, Pernia O, Rodriguez-Antolin C, Rodriguez C, Sanchez Cabo F, Soto J, Rosas R, Lopez-Magallon S, Esteban Rodriguez I, et al: DNA methylation of miR-7 is a mechanism involved in platinum response through MAFG overexpression in cancer cells. Theranostics. 7:4118–4134. 2017.PubMed/NCBI View Article : Google Scholar
38	Li X, Jin Y, Mu Z, Chen W and Jiang S: MicroRNA-146a-5p enhances cisplatininduced apoptosis in ovarian cancer cells by targeting multiple anti-apoptotic genes. Int J Oncol. 51:327–335. 2017.PubMed/NCBI View Article : Google Scholar
39	Jiang Y, Jiang J, Jia H, Qiao Z and Zhang J: Recovery of miR-139-5p in ovarian cancer reverses cisplatin resistance by targeting C-Jun. Cell Physiol Biochem. 51:129–141. 2018.PubMed/NCBI View Article : Google Scholar
40	Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006.PubMed/NCBI View Article : Google Scholar
41	Poyan Mehr A, Tran MT, Ralto KM, Leaf DE, Washco V, Messmer J, Lerner A, Kher A, Kim SH, Khoury CC, et al: De novo NAD⁺ biosynthetic impairment in acute kidney injury in humans. Nat Med. 24:1351–1359. 2018.PubMed/NCBI View Article : Google Scholar
42	Sahm F, Oezen I, Opitz CA, Radlwimmer B, von Deimling A, Ahrendt T, Adams S, Bode HB, Guillemin GJ, Wick W and Platten M: The endogenous tryptophan metabolite and NAD+ precursor quinolinic acid confers resistance of gliomas to oxidative stress. Cancer Res. 73:3225–3234. 2013.PubMed/NCBI View Article : Google Scholar
43	Ishidoh K, Kamemura N, Imagawa T, Oda M, Sakurai J and Katunuma N: Quinolinate phosphoribosyl transferase, a key enzyme in de novo NAD(+) synthesis, suppresses spontaneous cell death by inhibiting overproduction of active-caspase-3. Biochim Biophys Acta. 1803:527–533. 2010.PubMed/NCBI View Article : Google Scholar
44	Liu M, Bamodu OA, Huang WC, Zucha MA, Lin YK, Wu ATH, Huang CC, Lee WH, Yuan CC, Hsiao M, et al: 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway. Toxicol Appl Pharmacol. 325:48–60. 2017.PubMed/NCBI View Article : Google Scholar
45	Teng P, Jiao Y, Hao M and Tang X: microRNA-383 suppresses the P13K-AKT-MTOR signaling pathway to inhibit development of cervical cancer via downregulating PARP2. J Cell Biochem. 117:5243–5252. 2018.PubMed/NCBI View Article : Google Scholar
46	Zhang H, Gong J, Zhang H and Kong D: Induction of apoptosis and reversal of permeability glycoprotein-mediated multidrug resistance of MCF-7/ADM by ginsenoside Rh2. Int J Clin Exp Pathol. 8:4444–4456. 2015.PubMed/NCBI